KalVista ends a PhII study ear­ly af­ter pa­tients suf­fer se­vere and life-threat­en­ing side ef­fects

KalVista took a beat­ing Tues­day af­ter an­nounc­ing it would scrap a Phase II tri­al for one of its ex­per­i­men­tal drugs.

The biotech said in an ear­ly morn­ing press re­lease that it is ter­mi­nat­ing the study for KVD824 af­ter mul­ti­ple pa­tients in every treat­ment group saw un­safe, el­e­vat­ed lev­els of cer­tain liv­er en­zymes. By end­ing the tri­al now, KalVista hopes to save some mon­ey and fun­nel it to­ward an­oth­er study for its lead pro­gram, CEO An­drew Crock­ett said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER